ARS Pharmaceuticals Taps Dynavax Veteran Casale as President to Drive Commercial Expansion
Event summary
- ARS Pharmaceuticals appoints Donn Casale as President effective June 1, 2026.
- Casale brings 25 years of biopharmaceutical commercial experience, including scaling Dynavax's HEPLISAV-B to $300M in revenue.
- He will oversee global commercial operations for neffy® and expansion into chronic spontaneous urticaria (CSU).
- Richard Lowenthal remains CEO, focusing on strategic leadership.
The big picture
ARS Pharmaceuticals is bolstering its leadership to scale neffy, the first needle-free epinephrine nasal spray, in a competitive allergy treatment market. Casale's track record in commercializing high-growth products suggests ARS Pharma is prioritizing rapid market penetration ahead of potential entrants. His experience in payor access strategy could be critical as the company expands into chronic conditions like CSU.
What we're watching
- Commercial Execution
- How Casale's retail channel expertise will accelerate neffy adoption.
- Market Expansion
- The pace at which ARS Pharma advances into chronic spontaneous urticaria (CSU).
- Strategic Fit
- Whether Casale's background in vaccines aligns with ARS Pharma's allergy-focused pipeline.